InvestorsHub Logo
Followers 1
Posts 87
Boards Moderated 0
Alias Born 04/06/2016

Re: None

Thursday, 04/21/2016 8:44:50 AM

Thursday, April 21, 2016 8:44:50 AM

Post# of 140474
I would think the TRXC FDA rejection would cause TITXF to reconsider the cadaver approach. Human trials, although time consuming and more costly, would be a safer approach to FDA approval.